The obese gene (OB) product, leptin, has been shown to exert control on metabolic processes such as food intake and body weight homeostasis, possibly through a neuropeptide Y (NPY) neurotransmission. More recently, leptin has been shown to control several neuroendocrine axes, modulating pituitary hormone secretions in function of metabolic conditions. Since in the rat growth hormone (GH) secretion is dependent upon prevailing metabolic conditions, and NPY has been shown to be implicated in the feedback mechanisms of this hormone, we reasoned that leptin could also exert control over GH secretion and we examined this hypothesis in male rats submitted to a 3-day fast. Circulating leptin concentrations measured by RIA abruptly fell to low values after 24 h of fasting and remained low thereafter. Upon refeeding, leptin secretion regularly increased. As shown by others, pulsatile GH secretion had disappeared after 3 days of fasting. Centrally administered leptin (10 µg/day, i.c.v. infusion initiated at the beginning of the fasting period) totally prevented the disappearance of pulsatile GH secretion. No leak of centrally administered leptin to the general circulation was observed. Infusing the same amount of leptin intracerebroventricularly to rats receiving ad libitum feeding produced a severe reduction in food intake but maintained a normal GH secretory pattern. In contrast, pair-fed rats, submitted to the same food restriction, exhibited a marked reduction in GH secretion. Hypothalamic NPY gene expression, estimated by Northern blot analysis, was significantly increased in fasting rats, and decreased in leptin-treated, fasting rats. In rats receiving ad libitum feeding, leptin treatment reduced NPY gene expression, consistent with the observed reduction in food intake, whereas pair-fed animals logically exhibited increased NPY gene expression. In both situations with reduced feeding, normal GH secretion was seen in leptin-treated animals exhibiting low NPY gene expression, whereas decreased or abolished GH secretion was seen in animals not receiving leptin and exhibiting increased NPY mRNA levels. Interestingly, despite maintenance of normal GH secretion in leptin-treated, fasting rats, plasma IGF-I levels were low, as in vehicle-treated rats. Indeed, hepatic gene expression for both GH receptor and IGF-I was markedly reduced by fasting, and no correction was seen with leptin treatment. In summary, the regulation of GH secretion, at least the changes linked with malnutrition, appears to be dependent upon a leptin signal, perceived centrally, possibly related to circulating levels of this new hormone. The present data suggest that leptin can rescue normal pulsatile GH secretion by preventing the documented inhibitory action of NPY on GH secretion.

Keywords:
Leptin, Neuropeptide Y, Insulin-like growth factors, Fasting, Pulsatility
1.
Bertherat J, Bluet-Pajot M-T, Epelbaum J: Neuroendocrine regulation of growth hormone. Eur J Endocrinol 1995;132:12–24.
2.
Tannenbaum GS, Martin JB: Evidence for an endogenous ultradian rhythm governing growth hormone secretion in the rat. Endocrinology 1976;98:562–570.
3.
Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factor. Endocr Rev 1994;15:80–101.
4.
Tannenbaum GS, Rorstad O, Brazeau P: Effect of prolonged food deprivation on the ultradian growth hormone rhythm and immunoreactive somatostatin levels in the rat. Endocrinology 1979;104:1733–1738.
5.
Okada K, Sugihara H, Minami S, Wakabayashi I: Effect of parenteral administration of selected nutrients and central injection of antiserum to neuropeptide Y on growth hormone secretory pattern in food-deprived rats. Neuroendocrinology 1993;57:678–686.
6.
Tannenbaum GS: Growth hormone secretory dynamics in streptozotocin diabetes – Evidence of a role for endogenous circulating somatostatin. Endocrinology 1981;108:76–82.
7.
Pellegrini E, Bluet-Pajot M-T, Mounier F, Bennett P, Kordon C, Epelbaum J: Central administration of a growth hormone (GH) receptor mRNA antisense increases GH pulsatility and decreases hypothalamic somatostatin expression in rats. J Neurosci 1996;16:8140–8148.
8.
Pellegrini E, Carmignac DF, Bluet-Pajot M-T, Mounier F, Bennett P, Epelbaum J, Robinson ICAF: Intrahypothalamic growth hormone feedback: From dwarfism to acromegaly in the rat. Endocrinology 1997;138:4543–4551.
9.
Chan YY, Steiner RA, Clifton DK: Regulation of hypothalamic neuropeptide-Y neurons by growth hormone in the rat. Endocrinology 1996;137:1319–1325.
10.
Bai FL, Yamoto M, Shiotani Y, Emson PC, Smith AD, Powell JL, Tahyama M: An arcuato-paraventricular and dorsomedial hypothalamic neuropeptide Y containing system which lacks noradrenaline in the rat. Brain Res 1985;331:172–175.
11.
Hisano S, Tsuruo Y, Kagotani Y, Daikoku S, Chihara K: Immunohistochemical evidence for synaptic connections between neuropeptide Y-containing axons and periventricular somatostatin neurons in the anterior hypothalamus in rats. Brain Res 1990;520:170–177.
12.
Kamegai J, Minami S, Sugihara H, Higughi H, Wakabayashi I: Growth hormone induces expression of the c-fos gene on hypothalamic neuropeptide-Y and SRIH neurons in hypophysectomized rats. Endocrinology 1994;135:2765–2771.
13.
McDonald JK, Lumpkin MD, Samson WK, McCann SMM: Neuropeptide Y affects secretion of luteinizing hormone and growth hormone in ovariectomized rats. Proc Natl Acad Sci USA 1985;82:561–564.
14.
Rettori V, Milenkovic L, Aguila MC, McCann SM: Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge. Endocrinology 1990;126:2296–2301.
15.
Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML: Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and somatotropic axis in intact adult female rats. Endocrinology 1993;132:224–234.
16.
Gruaz NM, Pierroz DD, Rohner-Jeanrenaud F, Sizonenko PC, Aubert ML: Evidence that neuropeptide Y could represent a neuroendocrine inhibitor of sexual maturation in unfavorable metabolic conditions in the rat. Endocrinology 1993;133:1891–1895.
17.
Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML: Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor-I secretion in intact adult male rats. Endocrinology 1996;137:3–12.
18.
Beck B, Jhanwar-Unijal M, Burlet A, Chapleur-Chateau M, Leibowitz SF, Burlet C: Rapid and localized alterations of neuropeptide Y in discrete hypothalamic nuclei with feeding status. Brain Res 1990;528:245–249.
19.
Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS: Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 1991;88:10931–10935.
20.
Williams G, Steel JH, Cardoso H, Ghatei MA, Lee YC, Gill JS, Burrin JM, Polak JM, Bloom SR: Increased hypothalamic neuropeptide Y concentrations in diabetic rats. Diabetes 1988;37:763–772.
21.
Sahu A, Sninsky CA, Phelps CP, Dube MG, Kalra PS, Kalra SP: Neuropeptide Y release from the paraventricular nucleus increases in association with hyperphagia in streptozotocin-diabetic rats. Endocrinology 1992;131:2979–2985.
22.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:424–432.
23.
Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540–543.
24.
Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hofmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rsteck PJ Jr, Schoner B, Smith D, Tinsley FC, Zhang XY, Heiman M: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530–532.
25.
Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG: Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996;98:1101–1106.
26.
Chehab F, Lim M, Lu R: Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996;12:318–320.
27.
Barash IA, Cheung CC, Weigle DS, Ren H, Kabitting EB, Kuijer JL, Clifton DK, Steiner RA: Leptin is a metabolic signal to the reproductive system. Endocrinology 1996;137:3144–3147.
28.
Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, Trayhurn P: Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. J Neuroendocrinol 1996;8:733–735.
29.
Hakansson ML, Hulting AL, Meister B: Expression of leptin receptor mRNA in the hypothalamic arcuate nucleus-relationship with NPY neurones. Neuroreport 1996;7:3087–3092.
30.
Wang Q, Bing C, Al-Barazanji K, Mossakowaska DE, Wang XM, McBay DL, Neville WA, Taddayon M, Picavance L, Dryden S, Thomas MEA, McHale MT, Gloyer IS, Wilson S, Buckingham R, Arch JRS, Trayhurn P, Williams G: Interactions between leptin and hypothalamic neuropeptide Y neurones in the control of food intake and energy homeostasis in the rat. Diabetes 1997;46:335–341.
31.
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250–252.
32.
Carro E, Senaris R, Considine RV, Casanueva FF, Dieguez C: Regulation of in vivo growth hormone secretion by leptin. Endocrinology 1997;138:2203–2206.
33.
Gruaz NM, Arsenijevic Y, Wehrenberg WB, Sizonenko PC, Aubert ML: Growth hormone (GH) deprivation induced by passive immunization against rat GH-releasing factor does not disturb the course of sexual maturation and fertility in the female rat. Endocrinology 1994;135:509–519.
34.
Blum WF, Breier BH: Radioimmunoassay for IGFs and IGFBPs. Growth Regul 1994;4(suppl):11–19.
35.
Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extractions. Anal Biochem 1987;162:156–159.
36.
Tannebaum GS, Epelbaum J, Colle E, Brazeau P, Martin JB: Antiserum to somatostatin reverses starvation-induced inhibition of growth hormone but not insulin secretion. Endocrinology 1978;102:1909–1914.
37.
Leibowitz SF: Brain neuropeptide Y: An integrator of endocrine, metabolic and behavioral processes. Brain Res Bull 1991;27:333–337.
38.
Sahu A, Kalra SP: Neuropeptidergic regulation of feeding bahavior: neuropeptide Y. Trends Endocrinol Metab 1993;4:217–224.
39.
Pierroz DD, Heritier A, Lalaoui M, d’Allèves V, Blum WF, Aubert ML: Leptin is a metabolic signal for sexual function: Reciprocal changes in plasma leptin and arcuate nucleus NPY mRNA in two models of adverse metabolic conditions with hypogonadism. Endocrine Society, 79th Annual Meeting, June 1997, abstract OR24-6.
40.
Thissen JP, Triest S, Underwood LE, Maes M, Ketelslegers JM: Divergent responses of serum insulin-like growth factor I and liver growth hormone (GH) receptors to exogenous GH in protein-restricted rats. Endocrinology 1990;126:908–913.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.